Visit Wegovy (semaglutide) is approved by Health Canada specifically for the chronic weight management — an indication distinct from that of Ozempic, which contains the same active ingredient but is intended for the treatment of type 2 diabetes. This distinction, though often overlooked, is essential to understanding how this treatment is prescribed.
On this page
- What is Wegovy (semaglutide)?
- Wegovy and Ozempic: Same Active Ingredient, Different Indications
- How Does Semaglutide Affect Weight?
- Who is eligible for Wegovy?
- Protocol for Administration and Medical Monitoring
- Side Effects and Precautions
- Access to Wegovy in Quebec
- Myths and misconceptions
- Frequently asked questions
What is Wegovy (semaglutide)?
Visit semaglutide is a GLP-1 receptor agonist; GLP-1 is a hormone that regulates satiety and gastric emptying. Wegovy is the semaglutide formulation approved by Health Canada specifically for chronic weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity. The injection is administered once a week, subcutaneously.
To remember
- Wegovy contains semaglutide, a GLP-1 agonist
- Weekly subcutaneous injection
- Approved by Health Canada specifically for weight management, not for diabetes
- A different dosage from Ozempic, adjusted for weight management
- Always prescribed as a supplement to a diet and exercise plan
- Requires a prior medical evaluation and regular follow-up
Wegovy and Ozempic: Same Active Ingredient, Different Indications
Both Wegovy and Ozempic contain semaglutide, but Health Canada has approved them for distinct indications :
| Product | Approved Indication |
|---|---|
| Wegovy | Chronic Weight Management |
| Ozempic | Treatment of Type 2 Diabetes |
The dosage intervals and titration regimens also differ between the two products, tailored to their respective indications. The choice between the two is based strictly on medical evaluation, depending on the patient’s diagnosis and treatment goals.
How Does Semaglutide Affect Weight?
- Slower gastric emptying, prolonging the feeling of fullness
- Action on the appetite-regulating centers in the hypothalamus
- Reduced hunger cues between meals
Who is eligible for Wegovy?
Eligibility for Wegovy is based on specific clinical criteria, which are evaluated by a doctor:
| Criteria | General Threshold |
|---|---|
| Body Mass Index (BMI) | ≥ 30 kg/m² |
| BMI with associated comorbidities | ≥ 27 kg/m² |
| Preliminary Medical Evaluation | Required |
Protocol for Administration and Medical Monitoring
Stepwise titration
Treatment begins at a low dose, which is gradually increased over several weeks according to a specific regimen unique to Wegovy, under medical supervision.
Clinical follow-up required
- Comprehensive initial evaluation (medical history, comorbidities, contraindications)
- Periodic Monitoring of Treatment Response
- Adjustments Based on Tolerance and Clinical Goals
- Reassessment of the appropriateness of continuing treatment in the medium term
Side Effects and Precautions
Like any GLP-1 agonist, Wegovy has potential side effects, most commonly related to digestion (nausea, transient gastrointestinal effects at the start of treatment). There are certain contraindications, including specific personal or family medical histories. Only a healthcare professional can determine whether this treatment is appropriate based on a patient’s complete medical history.
Access to Wegovy in Quebec
Access to Wegovy requires a medical consultation to assess eligibility, medical history, and health goals. Our service locations in Quebec offer both in-person and telemedicine consultations for this type of assessment.
A comprehensive medical evaluation is the first step in determining whether Wegovy is an appropriate option for you. Make an appointment at one of our service locations in Quebec, or choose a online consultation. Companies interested in a wellness program for their employees can review our offerings for companies.
Myths and misconceptions
«Wegovy and Ozempic are exactly the same.»
Nuanced. Same molecule, but with different approved indications and dosage levels—Wegovy is intended for weight management, while Ozempic is intended for type 2 diabetes.
«Wegovy replaces diet and exercise»
False. Wegovy is approved as an adjunct to diet and exercise, never as a substitute.
«Anyone can get Wegovy»
False. A medical evaluation and a prescription are required, along with monitoring of clinical eligibility.
«The side effects are automatic and severe.»
Nuanced. Temporary digestive side effects are common at the start of treatment, but their severity varies greatly from person to person.
«The treatment is permanent.»
Nuanced. The duration of treatment is determined in consultation with the treating physician based on the clinical response and the established goals.
Frequently asked questions
Is Wegovy covered by RAMQ?
Coverage varies depending on the insurance plan and eligibility criteria. It is recommended that you check your specific coverage with your insurer or the RAMQ.
Can you take Wegovy if you already have Ozempic at home?
No, not without a medical evaluation. Even if the active ingredient is the same, the dosage and indication differ—only a doctor can determine the appropriate medication and dosage.
How long before I see results?
The timeframes vary from person to person depending on several individual factors. Regular medical follow-up allows for an assessment of progress and adjustments to the treatment plan.
Is Wegovy suitable for everyone?
No. Eligibility depends on specific clinical criteria (BMI, comorbidities, medical history) that are evaluated on a case-by-case basis during the medical consultation.
What is the difference between Wegovy and Saxenda?
Both are GLP-1 agonists, but they have different active ingredients (semaglutide vs. liraglutide) and different dosing schedules (weekly vs. daily). The choice depends on an individualized medical evaluation.
Sources
- Health Canada — Pharmaceutical Products Database
- National Institute for Excellence in Health and Social Services (INESSS)
- Quebec Ministry of Health and Social Services (MSSS)
- Quebec College of Physicians (CMQ) — Guidelines on Weight Management
- Quebec Health Insurance Board (RAMQ)
Recommended Reading
- Ozempic generic in Canada: price, access, and indications
- Saxenda in Quebec: Liraglutide for Weight Management
- Mounjaro in Quebec: The Complete Guide
- World Obesity Day: Medical Care in Quebec
- GLP-1 Agonists: A Comparison of Options Approved in Quebec
This information is provided for educational purposes only and is not a substitute for the advice of a healthcare professional. Consult a doctor if you have any questions about your health.
Omicron Clinic
Need to consult a doctor?
In-person or via telemedicine, anywhere in Quebec.
We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.
